Autopsy report · NCT02117024
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Cause of deathFunding or business
“Sponsor Decision; strategic - based on changing treatment landscape”
Life of this trial
- Registered 3 months before it started.
- Ran for about 3 years 9 months before it stopped.
- 66 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Heat Biologics
- Sponsor type
- Industry
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Viagenpumatucel-L; Metronomic Cyclophosphamide; Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
- Participants
- 66
- Sites
- 16
- Countries
- United States
Trials that died the same way
- Effects of Dietary Supplements on Nail and Hair Health
“Strategic change by sponsor” - Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
“Strategic sponsor decision” - Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
“Strategic direction of the sponsor changed” - Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation
“Strategic decision by Sponsor” - Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
“Strategic decision of Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.